BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
11/20/2026 2:04:44 AM | Browse: 0 | Download: 0
Publication Name World Journal of Gastroenterology
Manuscript ID 123331
Country China
ISSN 1007-9327 (print) and 2219-2840 (online)
Open Access This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution-NonCommercial (CC BY-NC 4.0) license. No commercial re-use. See Permissions. Published by Baishideng Publishing Group Inc.
Copyright ©Author(s) (or their employer(s)) 2026. No commercial re-use. See Permissions. Published by Baishideng Publishing Group Inc.
Article Reprints For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website http://www.wjgnet.com
Category Oncology
Manuscript Type Retrospective Cohort Study
Article Title Anlotinib plus radiotherapy or chemoradiotherapy in locally advanced or advanced esophageal squamous cell carcinoma: A multicohort, real-world study
Manuscript Source Unsolicited Manuscript
All Author List Guo-Jie Feng, Cheng-Rui Fu, Fan Wang, Jian-Cheng Li, Yue Jiang, Xin-Yi Wang, Bai-Hua Yang, Wen-Cai Xu, Yao-Wen Zhang, Xin-Yu Cheng, Xiao-Lin Ge, Xiao-Jie Xia, He-Ming Xi, Xue-Song Zhao, Hong-Bing Ma, Xi-Xi Zhao, Xin Wang and Bao-Sheng Li
ORCID
Author(s) ORCID Number
Fan Wang http://orcid.org/0000-0003-1407-4265
Hong-Bing Ma http://orcid.org/0009-0003-5575-0490
Xin Wang http://orcid.org/0000-0002-3149-108X
Bao-Sheng Li http://orcid.org/0000-0002-5390-7269
Funding Agency and Grant Number
Corresponding Author Xin Wang, Department of Radiation Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, No.17 Panjiayuannanli, Chaoyang District, Beijing 100000, China. beryl_wx2000@163.com
Key Words Anlotinib; Radiotherapy; Chemoradiotherapy; Locally advanced or advanced; Esophageal cancer; Esophageal squamous cell carcinoma
Core Tip Despite established standard treatments for locally advanced or advanced esophageal squamous cell carcinoma, patient survival and disease control remain suboptimal. This multicenter, real-world, retrospective study observed that anlotinib combined with radiotherapy or chemoradiotherapy (CRT) was associated with encouraging overall survival and disease control, with manageable toxicity. Propensity score matching analysis was further conducted to explore potential differences in efficacy between this regimen and standard CRT. These hypothesis-generating findings provide real-world evidence for anlotinib plus radiotherapy or CRT in this population and warrant further prospective investigation.
Publish Date 2026-11-20 02:04
Citation

Feng GJ, Fu CR, Wang F, Li JC, Jiang Y, Wang XY, Yang BH, Xu WC, Zhang YW, Cheng XY, Ge XL, Xia XJ, Xi HM, Zhao XS, Ma HB, Zhao XX, Wang X, Li BS. Anlotinib plus radiotherapy or chemoradiotherapy in locally advanced or advanced esophageal squamous cell carcinoma: A multicohort, real-world study. World J Gastroenterol 2027; 33(3): 123331

URL https://www.wjgnet.com/1007-9327/full/v33/i3/123331.htm
DOI https://doi.org/10.3748/wjg.123331
Full Article (PDF) WJG-33-123331-with-cover.pdf